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Abstract
!
Nonsteroidal anti-inflammatory drug intake is as-
sociated with a high prevalence of gastrointesti-
nal side effects, and severe cardiovascular adverse
reactions challenged the initial enthusiasm in cy-
clooxygenase-2 inhibitors. Recently, it was shown
that myrtucommulone, the active ingredient of
the Mediterranean shrub Myrtus communis, du-
ally and potently inhibits microsomal prostaglan-
din E2 synthase-1 and 5-lipoxygenase, suggesting
a substantial anti-inflammatory potential. How-
ever, one of the most important prerequisites for
the anti-inflammatory effects in vivo is sufficient
bioavailability of myrtucommulone. Therefore,
the present study was aimed to determine the
permeability and metabolic stability in vitro as
well as the systemic exposure of myrtucommu-
lone in rats. Permeation studies in the Caco-2
model revealed apparent permeability coefficient
values of 35.9 ·10−6 cm/s at 37°C in the apical to
basolateral direction, indicating a high absorption
of myrtucommulone. In a pilot rat study, average
plasma levels of 258.67 ng/mL were reached 1 h
after oral administration of 4mg/kg myrtucom-
mulone. We found that myrtucommulone under-
goes extensive phase I metabolism in human and
rat liver microsomes, yielding hydroxylated and
bihydroxylated as well as demethylated metab-
olites. Physiologically-based pharmacokinetic
modeling of myrtucommulone in the rat revealed
rapid and extensive distribution of myrtucommu-
lone in target tissues including plasma, skin,
muscle, and brain. As the development of selec-
tive microsomal prostaglandin E2 synthase-1 in-
hibitors represents an interesting alternative
strategy to traditional nonsteroidal anti-inflam-
matory drugs and cyclooxygenase-2 inhibitors
for the treatment of chronic inflammation, the
present study encourages further detailed phar-
macokinetic investigations on myrtucommulone.
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tIntroduction
!
Being far from a real breakthrough in the discov-
ery of safe NSAIDs [1], interest in alternative well-
tolerated anti-inflammatory herbal remedies is
growing.
Myrtle (Myrtus communis, Myrtaceae) is a Medi-
terranean shrub applied as a culinary spice andm Myrtus communis… Planta Med 2012; 78: 1932–1938flavoring agent for alcoholic beverages [2,3]. In
traditional folk medicine it has been used as an
antiseptic, antidiabetic, and anti-inflammatory
remedy. Scientific studies support the antibacte-
rial [4], antihyperglycemic [5,6], analgesic [7],
and antioxidant [8–10] properties. Recently, anti-
proliferative, antibacterial, and anti-inflamma-
tory effects of the ethanolic myrtle extract Myrta-
Fig. 1 Chemical struc-
tures of a MC and
b hyperforin.
1933Original Paperscine® in keratinocytes were reported, suggesting a therapeutic
value in the treatment of acne [11]. It was shown that MC
(l" Fig. 1) suppresses the biosynthesis of eicosanoids by direct in-
hibition of key enzymes like COX-1 and 5-LO in cell-free and cell-
based models [3]. Moreover, MC inhibits the mPGES-1-mediated
conversion of PGH2 to PGE2 in cell-free assays [12] as well as in
intact A549 cells and in human whole blood [12]. In vivo, i. p.
administration of MC (0.5, 1.5, and 4.5mg/kg) reduced the devel-
opment of mouse carrageenan-induced paw edema in a dose-de-
pendent manner and exerted anti-inflammatory efficacy in the
pleurisy model in mice [13]. However, no bioavailability studies
have been performed yet in animals or humans. Since poor ab-
sorption and/or extensive metabolism may play a crucial role in
limiting systemic availability, the present study aimed to deter-
mine the permeability of MC in Caco-2 cells and its metabolic
stability in rat and human liver microsomes as well as its oral
availability in a pilot rat study. Moreover, PBPK was applied to
estimate the distribution of MC in potential target tissues.Th
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Standards and reagents
MC with a purity of 99% was synthesized by Prof. Johann Jauch,
University of Saarland, Dept. of Organic Chemistry, Saarbruecken,
Germany [14]. Hyperforin dicyclohexyl ammonium salt (purity
99%), used as an internal standard, was supplied by Dr. W.
Schwabe Arzneimittel GmbH. Other reagents included tetrahy-
drofurane (gradient grade; Acros Organics SA), acetonitrile for
LC‑MS (Sigma-Aldrich), distilled water, tert-butyl methyl ether,
ethyl acetate (Merck), and ammonium formate (p.a.; VWR). Blank
human plasma was obtained from Deutsches Rotes Kreuz-Blut-
spendedienst, Mannheim, Germany. Pooled HLM, RLM, NADPH-
regenerating solutions A and B, and UGT reaction mix solutions
were purchased from BD Biosciences.
Caco-2 cells were seeded on Transwell® polycarbonate inserts
with a mean pore size of 0.4 µm (Corning Incorporated) and were
grown in DMEM, containing 25mM glucose supplemented with
10% FCS, 1% nonessential amino acids, and gentamycine (0.1mg/
mL). All media and HBSS were purchased from Biochrom AG.
HEPES, FITC-dextran, propranolol hydrochloride, and verapamil
were received from Sigma-Aldrich.
Microsomal incubation and sample preparation
MC stock solution (250 µg/mL) was prepared in acetonitrile-
water (50:50, v/v). The final incubation solutions for phase I re-
actions contained 50mM potassium phosphate buffer (pH 7.4),
7.5 µM MC, 1.3 µM NADP+, 3.3mM glucose-6-phosphate, 3.3mM
MgCl2, and 0.4 U/mL glucose-6-phosphate dehydrogenase in a
total volume of 250 µL. For phase II reactions, the final incubation
solutions consisted of 162.5 µL water, 20 µL of the UGT reaction
mix solution A containing 2mM UDP-glucuronic acid cofactor,
50 µL of the UGT reaction mix solution B (50mM Tris-HCl, 8mM
MgCl2, 25 µg/mL alamethicin), and MC (7.5 µM) in a total volume
of 250 µL. Reaction was initiated by the addition of 12.5 µL liver
microsomes (1mg/mL). The concentration of 7.5 µM was chosen
on the recommendation of the manufacturer. Controls were pre-
pared without cofactors. Aliquots of 50 µL were withdrawn after
15, 30, 60, and 120min from phase I incubations. Phase II incuba-
tion was stopped after 2 h by the addition of equal amounts of
ice-cold internal standard solution in acetonitrile. The samples
were kept on ice for 15min followed by centrifugation forGerbeth K et a15min (2500 g, at 4°C). Afterwards, the supernatants were di-
luted 1:50 and analyzed directly by LC‑MS/MS in the multiple
reaction monitoring mode. Metabolic stability of MC was deter-
mined in triplicate at each time point and after 2 h in case of the
phase II glucuronidation experiments.
Permeation of MC in the Caco-2 model
MC stock solution (1mg/mL) was prepared in DMSO. Then,
100 µL of the stock solution were diluted with HBSS containing
20mM HEPES adjusted to pH 6.5 (apical site) or pH 7.4 (basolat-
eral site) to yield a final concentration of 10 µg/mL MC and 1%
DMSO. This MC concentration was chosen to allow its detection
at the basolateral side even in case of poor permeability. For test-
ing the interaction of MC with P-glycoprotein (Pgp), the Pgp sub-
strate verapamil (50 µM) was added to the working solutions.
Permeation of MC was investigated in both directions at 37°C
with and without verapamil (50 µM) and additionally at 4°C in
the apical-to-basolateral (AB) direction (n = 6 each).
Prior to each experiment, Caco-2 monolayers were washed with
HBSS. TEER was measured before and after the transport experi-
ments. FITC-Dextran (MW 4400 g/mol) was used to gauge the in-
tegrity of the monolayers. Transports with propranolol hydro-
chloride (n = 3) served as a positive control for the functionality
of every cell passage. During incubation, the plates were agitated
at 37°C on a shaker at 120 rpm. Receiver fluid was withdrawn
after 15, 30, 60, 75, and 90min and replaced by equal volumes
of fresh buffer solution. At the end of the experiment, samples
were collected from both sides, and the plates werewashed three
times with pure HBSS followed by methanol. Then, each trans-
well filter was cut off, placed in 0.5mL methanol for 15min and
vortexed in order to lyse the cells. All samples were stored at
− 20°C. For analysis, an aliquot of 150 µL was mixed with equal
amounts of acetonitrile containing the I. S. at a concentration of
200 ng/mL. Solutions of pure methanol from cell lysis were
evaporated to dryness and reconstituted in a mixture of acetoni-
trile/buffer containing the internal standard before injection into
the LC‑MS system.
Calculation of permeability coefficients
The permeability coefficient (cm/s) was calculated by the follow-
ing equation:
Papp ¼ dCdt  VrAC0l. Myrtucommulone from Myrtus communis… Planta Med 2012; 78: 1932–1938
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Vr is the volume of the receiver chamber (mL); A is the surface
area of the cell monolayer; and C0 is the initial concentration of
the donor fluid (µg/mL).
Animal study
The rat study was approved by the local ethical committee on the
2nd November 2009 and given the approval number 2009/
0017055. Male Wistar Han rats (250 g; Harlan) were provided
with standard rodent chow and water in a controlled environ-
ment. Animal care complied with Italian regulations on protec-
tion of animals used for experimental and other scientific pur-
poses (Ministerial Decree 116192) as well as with the European
Economic Community regulations (Official Journal of E.C. L 358/
1 12/18/1986).
Following an overnight fast, 4mg/kg MC (0.5mL of a MC-solution
2mg/mL) were orally administered to three rats. The control
group (n = 3) received vehicle (0.5mL) consisting of 0.5% car-
boxymethylcellulose and 10% Tween-20. Food was allowed 4 h
after MC administration. Blood samples were taken from treated
rats 1, 4, 8, 14, 24, and 48 h after MC administration and from ve-
hicle-treated rats 4 h after vehicle administration. Approximately
4mL blood were collected by intracardiac puncture into citrate
tubes (0.1M). Blood samples were centrifuged, and the superna-
tants (plasma fraction) were stored at − 20°C until analysis.
Sample preparation of rat plasma samples
Based on the LC‑MS/MS method described elsewhere [15] dem-
onstrating cross-validation between rat and human plasma, cali-
bration samples were prepared by spiking 1mL of human plasma
with 50 µL of the particular spike solution to achieve concentra-
tions of 1.0, 2.5, 5.0, 10.0, 25.0, 50.0, 75.0, and 100.0 ng/mL of MC,
respectively. Accordingly, 1mL of thawed plasma samples was
spikedwith 50 µL acetonitrile. Furthermore, 50 µL of the I.S. solu-
tion containing 100 ng internal standard were added to all sam-
ples.
Following extraction for 25min with 5mL 20% ethyl acetate in
tert-butyl methyl ether in a horizontal position on a flatbed
mixer and centrifugation for 15min (2500 g, 10°C), the organic
layer was evaporated to dryness, and the residuewas redissolved
in 100 µL mobile phase. Then, the samples were sonicated for an-
other minute and centrifuged for 5min (2500 g, 10°C). Finally,
50 µL of the supernatant were injected into the LC‑MS/MS sys-
tem. Samples showing a concentration > 100 ng/mL were diluted
1:10 in order to fit the validated concentration range.
LC‑MS/MS
Liquid chromatography was performed on an Agilent 1200 series
withaGeminiC6phenylcolumn(Phenomenex), 250 × 4.6mmi.d.;
5 µm and a Gemini C6 phenyl security guard cartridge (Phenom-
enex) 4 × 3mm at a flow rate of 0.6mL/min and column temper-
ature of 40°C in a run time of 15min. The mobile phase consisted
of acetonitrile:water (85:15 v/v) containing 6mM ammonium
formate. The chromatographic run was divided into three time
segments starting with 0–5min running into waste, followed by
5–12min directed towardsMS and finally 12–15min running in-
to waste again.
MS analysis was performed on an Agilent Triple Quad mass spec-
trometer equippedwith an ESI source in the negative ionmode at
300°C. The precursor ion at m/z 667.5 and the fragment ion of
highest intensity atm/z 195.0 were selected for MRM of MC; sim-
ilarly, the ions at m/z 535.5 and 383.2 were used for the internalGerbeth K et al. Myrtucommulone from Myrtus communis… Planta Med 2012; 78: 1standard hyperforin. Data acquisition and processing was carried
out with the Mass Hunter software. The detailed method and its
validation are published elsewhere [15]. In brief, linearity could
be proven in the range of 1–100 ng/mL with r > 0.998. The great-
est deviation of the calculated from the nominal concentration
was found to be − 13.8% at the low concentration level. The rela-
tive standard deviation ranged between 1.4% at the high and
11.8% at the low concentration level, meeting thus the require-
ments for accuracy and precision for bioanalytical methods [16].
The mean relative recoveries of MC were determined to be
92.9 ± 9.1%, 76.0 ± 12.2%, and 79.5 ± 2.1% at the low, mid, and
high concentration level, respectively. In plasma, MC was found
to be stable upon storage at room temperature for at least 6 h
and at − 20°C for at least 6 months. Processed samples of MC
were stable in the autosampler for at least 24 h. Moreover, the
stability of MC was not affected by three freeze/thaw cycles.
HPLC‑UV
For the determination of propranolol hydrochloride, standard so-
lutions at concentrations of 0.207, 7.4, and 37.0 µg/mL were pre-
pared by dissolving propranolol in methanol and diluting the
stock solution with transport buffer (HBSS). Chromatographic
separation was achieved within 4min using an endcapped RP-
18 column (Purospher 125mm×4mm, 5 µm particle size; Agi-
lent) at a flow rate of 0.8mL/min (isocratic conditions). The mo-
bile phase consisted ofmethanol: 0.1M sodium dihydrogenphos-
phate solution pH 3.0, (60:40, v/v). Samples were detected by a
photo diode array detector (Agilent Technologies) at 230 nm.
Sample concentrationwas calculated using theMass Hunter soft-
ware.
Pharmacokinetics and PBPK modeling
Basic pharmacokinetic parameters (peak concentrations, Cmax;
concentration peak time, tmax; area-under-the-curve, AUC0-t;
and elimination half-life, t½) for MC were determined by the sta-
tistical software package BiAS (v10.0). The PKSim (version 4.1;
Bayer Technology Services GmbH) algorithm was utilized for the
present PBPK model in the rat [17,18]. Based on the lipophilicity
and solubility of MC blood flow, limited partitioning was as-
sumed. Initial inputs to the model for MC included molecular
weight (668.4 D), calculated LogP of 4.5 (based on structure),
measured a pKa of 5, measured aqueous solubility of 90 µM, mea-
sured protein binding of 99.9% (using ultracentrifugation), and
an estimated oral clearance of 4.7 L/h/kg based on the mean con-
centration-time data obtained in this study.Results and Discussion
!
MC undergoes extensive phase I metabolism in human liver mi-
crosomes. Thus after 15min of incubation with HLM, more than
50% of the initial MCwasmetabolized, and around 10% remained
after 120min. In RLM, phase I metabolism also occurred at an ex-
tensive but overall slower rate with nearly 100% of the initial MC
concentration being detectable after 15min, decreasing to 70%
after 30min, ending up with 45% after 120min incubation time.
Just as the control incubations without cofactors, the glucuroni-
dation experiments showed no decrease in MC concentration,
suggesting that MC is not susceptible to glucuronidation (data
not shown).
Screening of the incubation solutions in the full-scan modus re-
vealed various metabolites with mass shifts of + 16, + 32, and932–1938
Fig. 3 Characteristic fragmentation pattern of
MC.
Fig. 2 Full scan of MC incubation solution in HLM
containing NADPH-regenerating system after
60min in comparison to MC control sample (gray
line) lacking cofactor solutions.
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t− 14 u compared to MC that could not be detected in the control
samples (l" Fig. 2). Theywere identified on the basis of their com-
parable fragmentation pattern with MC (l" Fig. 3). Product ion
scans were performed to confirm the full scan results (l" Fig. 4).
Ion masses of m/z 698.4 (MC + 2OH), 683.2 (MC +OH), 667.5
(MC), 653.4 (MC –CH3), 623.4 (MC –C3H7) were chosen as precur-
sor ions. Control samples revealed only the peaks at t = 4.1min
and 8.1min (MC). Both the peak at 4.1min and the peak at
5.6min in the incubation solution did not yield the characteristic
MC fragmentation pattern, indicating no relation to MC (peaks
No. 1 and 2 in l" Table 1). The other peaks showed one or more
characteristic fragments of MC indicating a link to the parent
compound (l" Table 1). Peaks No. 3 and 5 yielded the parent com-
pound, suggesting the formation of some polar metabolites that
are obviously unstable in themass spectrometer fragmenting im-
mediately to MC. Hence, it may be concluded that phase I metab-
olism results in hydroxylated, bihydroxylated, and demethylated
metabolites and some other minor polar compounds. Screening
of plasma samples from MC-treated rats confirmed the presence
of these metabolites and the absence of glucuronidated conju-
gates. Moreover no sulphated conjugates could be identified in
rats, suggesting that MC is mainly subject to phase I but not to
phase II metabolism.Gerbeth K et aAn almost linear transport of MC was observed across the Caco-2
monolayer (l" Fig. 5), the validity of which was proven by TEER
values > 250 Ω cm2, the impermeability of FITC-dextran, and Papp
values of propranolol (34.66 ·10−6 cm/s) corresponding to the lit-
erature [19,20]. In the AB direction, MC was highly permeable
with Papp values of 35.9 ·10−6 cm/s at 37°C and 14.1 ·10−6 cm/s at
4°C.
The addition of verapamil at 37°C resulted in a Papp value of
14.0 ·10−6 cm/s, indicating that MC is not a Pgp substrate as the
MC concentrations in the receiver compartment were not in-
creased. The lower Papp value at 4°C suggests that active trans-
port (sensitive to temperature) may play a role in the absorption
of MC. As expected, Papp values were lower in the basolateral-to-
apical BA direction than in the absorptive direction. At 37°C,
the BA Papp values were determined to be 3.1 ·10−6 cm/s and
4.4 ·10−6 cm/s upon the addition of verapamil, indicating that
MC is not subject to secretion processes. Around 29.8–53.9% of
the initial MC concentration was detected in the cells in the ab-
sorptive and 5.3–9.2% in the secretory direction. However, be-
cause of the high Papp value in the absorptive direction, accumu-
lation in the cells and/or in the filter membrane was not paid fur-
ther attention. The observed high MC permeability, in spite of its
relatively highMW (667Da) and low aqueous solubility of 90 µM,
may be thus attributed to its lipophilicity and possible participa-l. Myrtucommulone from Myrtus communis… Planta Med 2012; 78: 1932–1938
Table 1 Overview of MC metabolites (product ion scan).
Peak number Retention time (min) Product ion Characteristic fragment Metabolism
1 4.1 483.2 – –
2 5.6 667.5 – –
3 5.7 667.5 431.5 unknown
4 5.8 653.4 415.4 demethylation
5 5.9 667.5 429.0 unknown
6 6.1 653.4 416.9 demethylation
7 6.25 623.4 428.6 demethylation
8 6.4 623.4 429.0 demethylation
9 6.6 683.2 446.6; 265.3 hydroxylation
10 6.7 652.1 249.2; 431.1 demethylation
11 6.9 626.2 195.1; 249.2; 431.1; 485.2 demethylation
12 7.0 625.9; 626.7 195.1; 431.1 demethylation
13 7.1 653.4 416.9 demethylation
14 7.2 698.1 195.1; 249.2; 431.1 dihydroxylation
15 7.3 697.6 431.1 dihydroxylation
MC 8.1 667.5 195.1; 249.2; 431.3; 485.2 parent compound
Fig. 4 Product ion scan of MC incubation solution
(black line) in HLM containing NADPH-regenerating
system in comparison to MC control sample (gray
line) lacking cofactor solutions.
Fig. 5 Amount of MC (% of the initial concentra-
tion) transported over the time (0–90min) under
different conditions in the Caco-2 model.
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ttion of active transport carriers in absorption. According to Yee,
Papp values > 10 ·10−6 cm/s reflect high absorption in vivo [20,
21]. Hence it may be assumed thatMC, not being subject to active
efflux mechanisms, might be well absorbed in humans.
After oral administration of 4mg/kg MC to rats, maximum plas-
ma concentrations of 190.0, 182.7, and 403.3 ng/mL were consis-
tently attained at 1 hour post-dose. The areas under the plasma
concentration curve AUC0–48 h (calculated using the trapezoidal
rule in SigmaPlot v11.0) were 658.3, 548.1, and 1646.9 ng/mL*h,
respectively. Parameter estimates obtained from the mean con-Gerbeth K et al. Myrtucommulone from Myrtus communis… Planta Med 2012; 78: 1centration-time curve as depicted in l" Fig. 6 (top) are Cmax of
258.6 ng/mL, tmax of 1 h, and a t½ of 10.3 h. The achieved plasma
levels exceeded the expectations regarding the availability of a
non-soluble, highly lipophilic, metabolically instable drug and
may be attributed to the high permeability of MC observed in
the Caco-2 model. Based on the applied dose and the resulting
mean plasma concentration-time curve, a clearance (CL/F) of
4.7 L/h/kg, and a volume of distribution (Vd/F) of 70.1 L/kg may
be assumed. The calculated clearance is in line with the extensive
metabolism observed for MC in vitro. Furthermore, the high vol-932–1938
Fig. 6 Top: Average plasma concentration profile of MC after oral admin-
istration of 4mg/kg MC to rats. The values represent the mean concentra-
tions ± SD of three rats. The 14-h value could not be analyzed in two rats
because of too small blood volume. Center: Simulated MC plasma-concen-
tration profiles in rats in comparison to the observed plasma concentra-
tions. Circles are mean values ± SD of three rats, with the exception of the
14-h value. Bottom: Simulated distribution of MC in different target tissues
based on PBPK modeling.
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tume of distribution indicates an intensive uptake of MC in vari-
ous tissues. Nevertheless, given the small number of animals in
this pilot study, verification of the obtained parameter estimates
is recommended in studies of a larger scale. No physical signs of
distress were noted in any of the three rats during the study.
Finally, PBPK modeling was applied to provide insights into the
disposition of MC in potential target tissues. As seen in l" Fig. 6,
center, the observed and simulated plasma-concentration-time
profiles of MC were comparable, indicating the suitability of the
applied PBPK model to predict systemic MC exposure. AccordingGerbeth K et ato this model, a rapid and extensive drug distribution is sug-
gested, which is underlined by the high volume of distribution
determined for MC (l" Fig. 6, bottom). Notably, highly perfused
tissues (e.g., liver) mimic the plasma concentration time course.
Tissue exposures predicted for skin, muscle, and brain indicate
that multicompartment kinetic behavior is likely and that some
degree of accumulation in these organs is possible. It may be as-
sumed thatMC reaches a plateau in the skin and brain after single
oral dosing that exceeds the plasma concentrations at the end of
the dosing interval. This underlines the pharmacological effects
of MC proposed in a keratinocyte model [11]. In contrast to skin,
data on potential effects of MC on the central nervous system do
not exist yet, but the observed accumulation of MC in brain tissue
encourages further studies evaluating possible anti-inflamma-
tory actions in the CNS. Of course, these simulations represent a
preliminary projection of MC disposition in rats and should be
confirmed by future biodistribution studies.
Against the background that selective mPGES-1 inhibitors repre-
sent an interesting alternative strategy to traditional NSAIDs and
COXIBs for the treatment of chronic inflammation [22], the
present study encourages further detailed pharmacokinetic in-
vestigations on MC.Conflict of Interest
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